Evidence map›Paper›PMID 41588397›Full record

ArticleBMC biology2026

Aegis: a transformer-based deep learning framework for the accurate identification of anticancer peptides.

Zexu Zhou, Lei Xie, Xiaolong Li, Yijie Wei, Xinwei Luo, Feitong Hong, Sijia Xie, Hao Lyu, Fuying Dao, Chengbing Huang and 2 more

Abstract read
In one paragraph

Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zexu Zhou *The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Lei Xie *School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Xiaolong LiThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Yijie WeiThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Xinwei LuoThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Feitong HongThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Sijia XieThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Hao LyuThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Fuying DaoSchool of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore.
Chengbing HuangAba Teachers University, Aba, 623002, China. 20049607@abtu.edu.cn.
Hui DingThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China. hding@uestc.edu.cn.
Huan YangYangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, 324000, China. yangh286@alumni.sysu.edu.cn.

Funding

Municipal Government of Quzhou 2024D008National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 62402207
6 · The paper itself

Abstract

backgroundAnticancer peptides (ACPs) are promising therapeutic agents with selective cytotoxicity toward cancer cells and minimal toxicity toward normal cells. However, the experimental identification and characterization of ACPs are often costly, time-consuming, and inefficient. Computational approaches provide promising alternatives for the rapid and accurate prediction of ACPs.

resultsHere, we introduce Aegis, a novel transformer-based deep learning framework designed for precise ACP identification. We systematically evaluated various machine learning and deep learning models via multiple feature extraction methods, including the composition of k-spaced amino acid pairs (CKSAAP), CTD composition (CTDC), CTD transition (CTDT), CTD distribution (CTDD), and pseudo amino acid composition (PAAC) methods. Comprehensive feature importance analyses via analysis of variance (ANOVA), ReliefF, and SHapley Additive exPlanations (SHAP) methods were performed, followed by incremental feature selection (IFS) to determine the optimal subset of discriminative features. Using the 103 optimal features identified via SHAP, Aegis achieves state-of-the-art (SOTA) performance on an independent testing dataset, outperforming existing ACP prediction models. Furthermore, compositional analysis revealed that ACP sequences are significantly enriched in positively charged and hydrophobic residues.

conclusionsOverall, our study demonstrates the exceptional potential of transformer-based deep learning for ACP identification, laying a foundation for future computational screening and the clinical development of novel ACPs.

Indexed as

Antineoplastic AgentsComputational BiologyDeep LearningPeptidesHumansAntineoplastic AgentsPeptidesAnticancer peptidesDeep learningIncremental feature selectionSHAPTransformer

Identifiers

PMID41588397
PMCPMC12918072

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.